MED-OLMESARTAN TABLET

Država: Kanada

Jezik: engleski

Izvor: Health Canada

Aktivni sastojci:

OLMESARTAN MEDOXOMIL

Dostupno od:

GENERIC MEDICAL PARTNERS INC

ATC koda:

C09CA08

INN (International ime):

OLMESARTAN MEDOXOMIL

Doziranje:

20MG

Farmaceutski oblik:

TABLET

Sastav:

OLMESARTAN MEDOXOMIL 20MG

Administracija rute:

ORAL

Jedinice u paketu:

2X14/100

Tip recepta:

Prescription

Područje terapije:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

Proizvod sažetak:

Active ingredient group (AIG) number: 0152496002; AHFS:

Status autorizacije:

APPROVED

Datum autorizacije:

2017-05-01

Svojstava lijeka

_Page 1 of 27_
PRODUCT MONOGRAPH
PR
MED-OLMESARTAN
Olmesartan Medoxomil Tablets
20 mg, and 40 mg olmesartan medoxomil,
Angiotensin II AT
1
Receptor
Blocker
GENERIC MEDICAL PARTNERS INC.
251 Consumers Road, Suite 1200
Toronto, Ontario
M2J 4R3
Date of Revision:
APRIL 24, 2017
Submission Control No: 178734, 204768
_Page 2 of 27_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
.................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
8
DRUG INTERACTIONS
...................................................................................................
10
DOSAGE AND ADMINISTRATION
...............................................................................
12
OVERDOSAGE
.................................................................................................................
14
ACTION AND CLINICAL PHARMACOLOGY
............................................................. 14
STORAGE AND STABILITY
..........................................................................................
16
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................. 16
PART II: SCIENTIFIC INFORMATION
................................................................................
17
PHARMACEUTICAL INFORMATION
...........................................................................
17
CLINICAL TRIALS
...........................................................................................................
18
DETAILED PHARMACOLOGY
............